Amendments to the Specification

It should be noted that the specification as filed includes underlined text. Text underlined in the specification as filed is indicated by a dashed underline to distinguish it from newly added text indicated by a solid underline as required by Patent and Trademark Office Rules.

Please replace the paragraph beginning at page 1, line 11, with the following paragraph:

-- This is a continuation-in-part of U.S. Application No. 09/958,713 filed on October 11, 2001, which is the United States national phase application under 35 U.S.C. § 371 ~~claims the benefit~~ of PCT Application No. PCT/US00/09839 filed on April 12, 2000, which claims priority to U.S. Provisional Patent Application No. 60/128,898 filed on April 12, 1999, all of which are incorporated herein by reference in their entirety. --

Please replace the paragraph beginning at page 5, line 14, with the following paragraph:

-- **Figs. 4A-F** show[s] the results of a study where PBMC from 8-20 normal human donors (A, C and E) and 20 rhesus macaques (B, D and F) were stimulated for 72 hours with a panel of "K", "D" or control ODN (3 μM). IL-6 (E and F) and IFN-α (A and B) levels in culture supernatants were determined by ELISA while cell proliferation was assessed by $[H]^3$ thymidine uptake (C and D). Note that D ODN induce the secretion of IFNα while K ODN induce cell proliferation and IL-6 production. All assays were performed in triplicate. Statistical significance was determined by ANOVA of log normalized data. * $p < 0.05$; ** $p < 0.01$. --

Please replace the paragraph beginning at page 5, line 22, with the following paragraph:

-- **Figs. 5A-C** shows the results of a study where PBMC from rhesus macaques (N = 12-20) were stimulated *in vitro* for 72 hours with a mixture of D19, D29 and D35 (1 μM each) or K3 and K123 (1.5 μM each). D122 and K163 were used in the control ODN mixture. Levels of IL-6 (B) and IFNα (C) in culture supernatants were measured by ELISA, while proliferation was measured by $[H]^3$-thymidine uptake (A). Statistical significance was determined by ANOVA of the normalized data. ** $p<0.01$. --

Please replace the paragraph beginning at page 15, line 3, with the following paragraph:

-- IFN-γ can be detected by sensitive immunoassays, such as an ELISA test that allows detection of individual cells producing IFN-γ. Minute amounts of IFN-γ can be detected indirectly by measuring IFN-induced proteins such as Mx protein. The induction of the synthesis of IP-10 has been used also to measure IFN-gamma concentrations. In addition, bioassays can be used to detect IFN-γ, such as an assay that employs induction of indoleamine 2,3-dioxygenase activity in 2D9 cells.--

Please replace the line 16 on page 47 as follows:

-- (SEQ ID NO: ~~127~~121) --

Please replace the paragraph beginning at page 51, line 18, with the following paragraph:

-- Oligonucleotides and antibodies: ODN were synthesized at the CBER core facility. Sequences of the CpG ODN used in this study are: 5'-TCGAGCGTTCTC-3' (K23, SEQ ID NO: 79) and 5'-GGtgcatcgatgcaggggGG-3' (D35, SEQ ID NO: 1). The control for K ODN was: 5'-TCAAGTGTTCTC-3' (SEQ ID NO: ~~140~~122) and for D ODN was: 5'-GgtgcatctatgcaggggGG-3' (SEQ ID NO: ~~141~~123). In this example, bases shown in capital letters are phosphorothioate while those in lower case are phosphodiester. CpG dinucleotides are underlined. All FITC, PE and cychrome labeled Mabs were purchased from Pharmingen (San Jose, CA). All ODNs used in this study contained <0.1 U/mg of endotoxin. --

Please replace line 23 on page 60 as follows:

-- AA3M: GGGCATGCATGGGGGG (SEQ ID NO:124~~: 142~~) --

Substitute Sequence Listing

Please replace the previously submitted sequence listing with the sequence listing enclosed herewith. A statement in compliance with 37 C.F.R. § 1.821 (f) is included herewith.